A DNA/RNA hybrid molecule engineered in a lab could be the next best thing for treating human immune system-based disorders (IMAGE)

Tokyo Medical and Dental University

A DNA/RNA hybrid molecule engineered in a lab could be the next best thing for treating human immune system-based disorders

Caption

(A) In normal mice, administration of HDO (red bar) more drastically suppresses α4β1 integrin gene expression in peripheral and splenic lymphocytes compared to antisense oligonucleotide (green bar). (B) In experimental autoimmune encephalomyelitis (EAE) mice, administration of HDO targeting α4β1 integrin after the onset of symptom has shown improvement in clinical score. (C) Administration of HDO targeting α4β1 integrin prior to the onset of EAE mice results in reduced Iba1-positive inflammatory cell infiltration (red) and improved demyelination (green) in Lumbar spinal cord.(D) In the mouse model of graft-versus-host-disease (GVHD), transplantation of spleen-derived T cells together with bone marrow cells after treatment with HDO targeting α4β1 integrin improved the survival curve. TCD : Transplanted bone marrow cells without spleen-derived T cells

Credit

Department of Neurology and Neurological Science, TMDU

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.